AKT1 and acute myeloid leukemia: Finally, to begin investigating the effects of AKT inhibition on GO and calicheamicin-γ1-based treatment of primary AML, we treated 3 AML specimens with various doses of calicheamicin-γ1 in the presence or absence of a relatively non-toxic dose of MK-2206 (1 μM); limited cell numbers precluded the simultaneous testing of GO in these assays.